Related Experiment Video

Updated: Jun 22, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway

Rong Zheng1, Li Wang, Junming Fan

  • 1Core Facility of Gene Engineered Mouse, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, PR China.

Cell Biology International
|June 16, 2009
PubMed

Insights

Autosomal recessive polycystic kidney disease (ARPKD) is a genetic disorder caused by PKHD1 mutations. Rapamycin, an mTOR inhibitor, may offer novel ARPKD therapy by affecting cell growth and cystogenesis pathways.

Area of Science:

  • Nephrology
  • Genetics
  • Molecular Biology

Background:

  • Autosomal recessive polycystic kidney disease (ARPKD) is a significant genetic disorder in pediatric nephrology.
  • Mutations in the polycystic kidney and hepatic disease gene 1 (PKHD1) are identified as the cause of ARPKD.
  • Mammalian target of rapamycin (mTOR) is a kinase regulating cell cycle, size, and proliferation, making it a target for anti-cystogenesis agents.

Purpose of the Study:

  • To investigate the relationship between decreased FPC and protein levels of mTOR.
  • To examine the inhibitory effects of rapamycin on mTOR, Hypoxia-inducible factor-1 alpha (HIF-1alpha), and vascular endothelial growth factor (VEGF) expression.
  • To explore the potential of targeting mTOR signaling as a novel therapeutic strategy for ARPKD.

Main Methods:

  • Utilized the human 293T cell line for experimental investigations.
  • Assessed protein levels of mTOR, HIF-1alpha, and VEGF.
  • Investigated the effects of rapamycin, a specific mTOR inhibitor.

Main Results:

  • Observed a relationship between decreased FPC and mTOR protein levels.
  • Demonstrated the inhibitory effects of rapamycin on mTOR, HIF-1alpha, and VEGF expression in 293T cells.
  • Provided insights into the role of mTOR signaling in ARPKD pathogenesis.

Conclusions:

  • Findings offer a platform for understanding FPC function and ARPKD pathogenesis.
  • Targeting mTOR signaling presents a potentially novel therapeutic approach for ARPKD.
  • Further research into FPC and mTOR pathways is warranted for ARPKD treatment development.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...